BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 36313417)

  • 1. The development of a novel signature based on the m
    Li H; Lin D; Wang X; Feng Z; Zhang J; Wang K
    Front Genet; 2022; 13():894080. PubMed ID: 36313417
    [No Abstract]   [Full Text] [Related]  

  • 2. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
    Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
    Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia.
    Li D; Liang J; Cheng C; Guo W; Li S; Song W; Song Z; Bai Y; Zhang Y; Wu X; Zhang W
    Front Cell Dev Biol; 2021; 9():770451. PubMed ID: 34869365
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma.
    Tan Y; Lu L; Liang X; Chen Y
    World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
    Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
    BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer.
    Lu M; Zhan H; Liu B; Li D; Li W; Chen X; Zhou X
    EPMA J; 2021 Dec; 12(4):589-604. PubMed ID: 34950253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of m6A-related lncRNAs-based signature for predicting the prognosis of patients with skin cutaneous melanoma.
    Lin W; Tan ZY; Fang XC
    SLAS Technol; 2024 Feb; 29(1):100101. PubMed ID: 37541541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of Biomarkers to Construct a Competing Endogenous RNA Network and Establishment of a Genomic-Clinicopathologic Nomogram to Predict Survival for Children with Rhabdoid Tumors of the Kidney.
    Wang X; Wu X; Li T; Cui M; Zhu L; Wang G; Guo F
    Biomed Res Int; 2020; 2020():5843874. PubMed ID: 32908900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Front Oncol; 2021; 11():663263. PubMed ID: 34123820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.
    Wang X; Meng Y; Liu C; Yang H; Zhou S
    J Oncol; 2022; 2022():9103259. PubMed ID: 36131791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
    Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
    J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.